Project Grant R00HL161469

Award Date 12/9/24
Completion Date 11/30/27
Dollars Obligated $249K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $2,139,180 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop innovative MRI methods that can simultaneously and efficiently evaluate both the cardiac and respiratory systems in pediatric cardiopulmonary diseases. The key products and services to be delivered include: Free-running cardiopulmonary imaging techniques to provide anatomical imaging and quantification of ventilation, perfusion, cardiac function,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $1,584,184 to Cedars-Sinai Medical Center to develop deep learning-based methods for precise phenotyping and outcomes prediction in valvular heart disease, particularly mitral valve disease. The key objectives are to: (i) automate the phenotyping of mitral regurgitation severity, systolic dysfunction, diastolic parameters, and...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), has awarded a $756,947 Project Grant (R01HL178117) to the University of Utah to assess myocardial fibrosis using spin-locked MRI techniques. This 4-year project (3/10/2025 - 12/31/2028) aims to: 1) study the value of different T1rho MRI methods and conventional MRI techniques in preclinical models of diffuse, focal, and radiofrequency-induced myocardial fibrosis;...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to develop advanced artificial intelligence (AI) methods for analyzing echocardiography images to predict biological cardiovascular age and identify risk factors for accelerated cardiovascular aging. The $791,114 award to Cedars-Sinai Medical Center will leverage echocardiography data from both healthcare cohorts and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $810,650 to Cedars-Sinai Medical Center to develop and validate an artificial intelligence (AI)-enabled system for characterizing fibrotic and calcific aortic valve tissue from computed tomography angiography (CTA) scans. The goal is to predict rapid aortic valve disease progression and risk of mortality and stroke following...
This Project Grant award of $401,613.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a novel protein-based MRI contrast agent for precision imaging of lung fibrosis. The primary goals are to create a stable and homogeneous collagen-targeted contrast agent called PROCA32.COLLAGENL, and then evaluate its in vivo imaging capabilities for early detection and monitoring of lung fibrosis progression and...
This Project Grant award, with a total funding amount of $1,276,293, was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award aims to develop a new clinical decision support (CDS) tool for early detection of cardiopulmonary deterioration events in hospitalized children. The key objectives are to: 1) Derive and validate a hospital-wide cardiopulmonary deterioration prediction model using...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), provides $167,588 to support the career development of Dr. Son Duong at the Icahn School of Medicine at Mount Sinai (ISMMS) into an independent investigator of artificial intelligence applications for cardiovascular imaging and patient risk prediction in tetralogy of Fallot and other congenital heart diseases. The key objectives are...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), which is part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $173,216 to Yale University to conduct a 5-year research project evaluating quantitative magnetic resonance imaging (MRI) biomarkers for assessing vascular disease, tissue ischemia, and fibrosis in patients with systemic sclerosis (scleroderma). The project aims to test whether MRI-based physiological biomarkers can...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837), supports a 5-year, $126,059 research project conducted by the University of Colorado-Denver. The project aims to utilize proximity extension assay technology to perform longitudinal proteomic analyses of children with congenital heart disease (CHD) in order to identify novel biomarkers and understand the systems biology underlying...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $248,970 to Cedars-Sinai Medical Center to develop a non-contrast, free-breathing 3D T1 mapping technique for quantifying myocardial fibrosis in pediatric cardiomyopathy patients. The key products and services to be delivered include:

  1. Implementing innovative k-space sampling and deep learning methods to achieve high-quality 3D cardiac T1 mapping with shorter scan and reconstruction times, overcoming the technical limitations of existing approaches.

  2. Automating the image analysis and fibrosis quantification pipeline using deep learning to enable clinical integration and improve accessibility of the information for patient care.

  3. Conducting a large-scale study of the novel 3D T1 mapping technique in a population of pediatric patients, making this the most comprehensive T1 mapping research to date in this patient group.

The award period runs from December 2024 to November 2027, supporting the development and clinical validation of this non-contrast cardiac imaging approach to better detect and quantify myocardial fibrosis in children with various heart diseases.

Generated 4/29/25, 4:56 AM